Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myelin basic protein (MBP)-specific autoreactive T cells are a subset of immune cells that recognize and respond to MBP, a key component of the myelin sheath in the central nervous system. These T cells are implicated in the pathogenesis of multiple sclerosis (MS) and other demyelinating autoimmune diseases, where they contribute to inflammation and destruction of myelin. They can be both CD4+ (helper) and CD8+ (cytotoxic) subsets and typically exhibit a pro-inflammatory phenotype producing cytokines such as TNF-alpha and IFN-gamma. Activation may occur due to molecular mimicry. Strategies such as "T cell vaccination" use attenuated autologous MBP-reactive clones to induce tolerance/deplete pathogenic populations.
T cell vaccination (attenuated autologous MBP-reactive clones to induce tolerance/deplete pathogenic populations)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myelin Basic Protein-Specific Autoreactive T Cells (MBP-specific autoreactive T cells).